ALT in “GLP-1 Eats Everything”
Altimmune, Inc.
Pemvidutide offers direct exposure to the obesity and metabolic-liver-disease markets, including demand for therapies with favorable body-composition outcomes.
ALT impact map — “GLP-1 Eats Everything”
How this story travels from the headline to ALT’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading ALT impact map…
Price history, marked with story events
Sep 3, 2025 – Sep 4, 2026 · 254 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
GLP-1 Eats Everything
Appetite suppression as a macro variable.
BULL side — Pemvidutide offers direct exposure to the obesity and metabolic-liver-disease markets, including demand for therapies with favorable body-composition outcomes.
Read the full GLP-1 Eats Everything story